This retatrutide wiki covers the investigational weight loss drug retatrutide: how it works, trial results, dosage, side effects, and availability.
Retatrutide is an investigational triple hormone receptor agonist developed by Eli Lilly for obesity and type 2 diabetes. It is not FDA-approved, it is not available by prescription, and there is no official retatrutide wiki page beyond clinical trial registries, peer-reviewed studies, and regulatory filings. This retatrutide wiki summarizes what is known about the weight loss drug retatrutide, including its meaning, mechanism, trial results, and safety profile.
What Is Retatrutide?
Retatrutide, also known as LY3437943, is a single molecule that activates three receptors: GIP, GLP-1, and glucagon. The term "retatrutide medication" is often used in search queries, but the drug remains an investigational product rather than an approved medicine.
The retatrutide meaning in scientific literature refers to its code name and its triple-agonist design. So what does retatrutide do? It combines GLP-1 and GIP appetite effects with glucagon receptor activity that may increase energy expenditure.
Retatrutide is being studied as an injectable treatment for:
- Obesity and overweight with weight-related conditions
- Type 2 diabetes
- Potential cardiovascular and metabolic outcomes
Retatrutide is not FDA-approved for human use in the United States. No pharmacy can legally dispense it outside a clinical trial.
How Retatrutide Works
Retatrutide binds to and activates GIP, GLP-1, and glucagon receptors. GLP-1 and GIP help reduce appetite and slow stomach emptying, while glucagon receptor activation may increase energy expenditure and fat oxidation.
This triple mechanism separates retatrutide from older GLP-1 drugs such as semaglutide and dual GIP/GLP-1 drugs such as tirzepatide. The balance of receptor activity is still being studied, and researchers do not fully understand which effects drive the largest weight loss.
| Drug | Receptors activated | US approval status | Reported weight loss |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | Approved for obesity | About 15% at 68 weeks |
| Tirzepatide (Zepbound) | GIP + GLP-1 | Approved for obesity | About 20-21% at 72 weeks |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational | Up to about 24% at 48 weeks in Phase 2 |
These numbers come from different trials with different designs. They cannot promise individual results, and direct comparisons are limited.
Retatrutide Clinical Trial Results and Weight Loss
The most cited retatrutide trial is a Phase 2 obesity study published in the New England Journal of Medicine in 2023. Participants without diabetes received weekly retatrutide or placebo for 48 weeks.
Average weight loss by dose in that trial:
| Weekly dose | Average weight loss at 48 weeks |
|---|---|
| 1 mg | About 8.7% |
| 4 mg | About 17.0% |
| 8 mg | About 22.8% |
| 12 mg | About 24.2% |
| Placebo | About 2.1% |
Phase 3 trials, including the TRIUMPH program, are ongoing. Results from those larger studies will determine whether retatrutide receives regulatory approval.
Retatrutide has not been proven to reduce heart attacks, strokes, or deaths. Outcome trials are still needed.
Retatrutide Dosage, Side Effects, and Safety
No validated retatrutide dosage exists outside clinical trials. In research settings, doses ranged from 1 mg to 12 mg once weekly, often with gradual titration to reduce gastrointestinal effects.
Side effects reported in retatrutide trials included:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
- Injection site reactions
Some participants experienced heart rate increases, and a few discontinued due to gastrointestinal symptoms. Anyone considering a weight loss medication should talk with a licensed healthcare professional about risks, benefits, and monitoring.
Many people search for retatrutide side effects before the drug is approved. The safest current answer is that long-term safety data are incomplete.
Searching for dosing information online can also lead to unverified advice. Dosing should only be done under medical supervision in an approved trial or prescription setting.
Availability, Legal Status, and Where to Buy Retatrutide
When Will Retatrutide Be Available?
When will retatrutide be available is a common question, and the honest answer is that no one knows yet. Eli Lilly has not announced an FDA submission date or a projected approval timeline.
Retatrutide must complete Phase 3 trials, and the company must submit a New Drug Application. The FDA then reviews the application, which can take 6 to 12 months or longer.
If approved, retatrutide would likely be available by prescription only. It would not be sold over the counter, and it would not be legal to buy from unregulated websites.
Some analysts speculate about a launch in the late 2020s, but those predictions are not official. Only Eli Lilly and the FDA can confirm a real timeline.
Where to Buy Retatrutide
Where to buy retatrutide is a risky search because the drug is not approved for human use. Some online vendors sell retatrutide as a "research chemical" or "for laboratory use only."
Buying retatrutide from those sources is not legal for personal use, and the products may be impure, mislabeled, or contaminated. The FDA has warned consumers about compounded and research-grade GLP-1 products.
Retatrutide is not a dietary supplement. It is an investigational prescription drug, and it should only be obtained through a clinical trial or, if approved in the future, a licensed pharmacy.
People also ask about buying retatrutide in forums and social media. Those sources cannot verify identity, purity, or sterility.
How Retatrutide Compares to Other Weight Loss Drugs
Researchers often compare cagrilintide vs retatrutide vs tirzepatide when reviewing next-generation obesity treatments. Each drug works differently and has a different approval status.
- Semaglutide is a GLP-1 agonist approved for obesity and diabetes.
- Tirzepatide is a dual GIP/GLP-1 agonist approved for obesity and diabetes.
- Cagrilintide is an amylin analog being studied alone and with semaglutide.
- Retatrutide is a triple agonist still in Phase 3 trials.
Some people also research other peptides alongside retatrutide, hoping to combine fat-loss and recovery compounds. There is no high-quality human evidence that these combinations are safe or effective, and retatrutide itself is not approved.
Retatrutide is not a cure for obesity, and it is not a replacement for diet, exercise, or medical care. Long-term data on weight maintenance, cardiovascular outcomes, and rare side effects are still being collected.
Frequently Asked Questions
Is retatrutide available in the United States?
No. Retatrutide is not FDA-approved, and it is not available by prescription in the United States. It can only be accessed through ongoing clinical trials. Buying it online as a research chemical is not legal for human use.
How much weight can you lose on retatrutide?
In a Phase 2 trial, participants without diabetes lost an average of up to 24.2% of their body weight at 48 weeks with the 12 mg weekly dose. Individual results varied, and the drug is not approved for weight loss. Phase 3 trial results are still pending.
What are the side effects of retatrutide?
Common side effects in trials included nausea, diarrhea, vomiting, constipation, and injection site reactions. Some people also experienced an increase in heart rate. Long-term safety data are not yet complete, so anyone interested should consult a healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.